HaystackAnalytics, a Mumbai based health-tech startup, supported by the Department of Science & Technology, Govt of India, has developed the first of its kind Universal Infectious Diseases (ID) Test in the country. The test deploys Next-Generation Sequencing (NGS) technology to identify existing and emerging infections, while providing information on drug resistance to support and identify correct treatment options for patients.

HaystackAnalytics has partnered with various diagnostic centers such as Unipath, Anderson, Sterling Accuris, Apollo Hospitals and over 20+ hospitals including AIIMS, to introduce their Sequencing based clinical products for TB and Covid in the past. The tests will be rolled out with the current partners in a phased manner over the next three months, and will be initially targeted at identifying and treating sepsis in Intensive Care Unit (ICU) patients, but gradually be made available to anyone suffering from a fever of unknown origin, by eradicating the need to conduct multiple tests. 

Dr Anirvan Chatterjee, Co Founder and CEO, HaystackAnalytics, said, “Leveraging the power of next generation sequencing and AI, the team of scientists and engineers at Haystack has been able to eliminate the need for a redundant and expensive battery of tests, with a single test. Our single point focus is to prevent every death caused due to treatable infections.”